Nuvation Bio (NUVB.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec11

HC Wainwright Maintains Nuvation Bio Buy Rating and Raises Target Price

18:52

Dec3

Nuvation Bio Inc.'s Chief Medical Officer Liu Dongfang sells company common stock

22:02

Nuvation Bio Announces Positive Phase 2 Trial Results for Oral Inhibitor Safusidenib

13:01

Dec2

Nuvation Bio Terminates NUV-1511 Program and Realigns Pipeline

09:58

Dec1

Nuvation Bio Inc. Launches IBTROZI and Reports Clinical Progress and Financial Status

15:09

Nov27

Nuvation Bio's Chief Medical Officer Sells Shares as Company Halts NUV-1511 Development

03:42

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 13.12 M, Net Income -55.79 M, EPS -0.1629

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 4.833 M, Net Income -59.01 M, EPS -0.1731

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 3.084 M, Net Income -53.24 M, EPS -0.16

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change